山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00719 山东新华制药股份

已收盘 12-04 16:08:13

5.770

-0.040

-0.69%

最高5.810	最低5.760	成交量63.52万
今开5.800	昨收5.810	日振幅0.86%
总市值39.37亿	流通市值11.25亿	总股本6.82亿
成交额367.27万	换手率0.33%	流通股本1.95亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00719","market":"HK","secType":"STK","nameCN":"山东新华制药股份","latestPrice":5.77,"timestamp":1733299693010,"preClose":5.81,"halted":0,"volume":635200,"delay":0,"floatShares":195000000,"shares":682407635,"eps":0.78762835,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.04,"latestTime":"12-04 16:08:13","open":5.8,"high":5.81,"low":5.76,"amount":3672724,"amplitude":0.008606,"askPrice":5.79,"askSize":16000,"bidPrice":5.77,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":0.6957368961748633,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1733362200000},"adr":0,"listingDate":851961600000,"adjPreClose":5.81,"dividendRate":0.050833,"openAndCloseTimeList":[[1733275800000,1733284800000],[1733288400000,1733299200000]],"volumeRatio":1.046389,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000756","market":"SZ","secType":"STK","nameCN":"新华制药","latestPrice":15.92,"timestamp":1733295831000,"preClose":16.23,"halted":0,"volume":7938997,"delay":0,"premium":"-66.12"}},"requestUrl":"/m/hq/s/00719/wiki","defaultTab":"wiki","newsList":[{"id":"2488900117","title":"南向资金12月3日净买入山东新华制药股份4.00万股 连续7日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2488900117","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488900117?lang=zh_cn&edition=full","pubTime":"2024-12-04 09:30","pubTimestamp":1733275807,"startTime":"0","endTime":"0","summary":"12月3日, 南向资金增持山东新华制药股份4.00万股，连续7日增持。截止当日收盘，港股通共持有山东新华制药股份9395.71万股，占流通股48.17%。港股通增持金额前五个股分别为美团-W、阿里巴巴-W、中国移动、腾讯控股、招商银行。山东新华制药股份近5个交易日上涨2.11%，港股通累计增持55.80万股；近20个交易日下跌5.07%，港股通累计增持189.14万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204093036abf424d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241204093036abf424d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00719","BK1191","BK1515"],"gpt_icon":0},{"id":"2488499239","title":"新华制药：全资子公司药品阿奇霉素干混悬剂通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2488499239","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488499239?lang=zh_cn&edition=full","pubTime":"2024-12-03 16:59","pubTimestamp":1733216384,"startTime":"0","endTime":"0","summary":"12月3日，新华制药公告，全资子公司新达制药收到国家药品监督管理局核准签发的阿奇霉素干混悬剂《药品补充申请批准通知书》，批准该药品通过仿制药质量和疗效一致性评价。阿奇霉素干混悬剂适用于治疗由指定微生物敏感菌株引起的多种感染，包括支气管炎、社区获得性肺炎、急性中耳炎、急性细菌性鼻窦炎等。该药品属国家医保目录乙类品种。文章来源：每日经济新闻原标题：新华制药：全资子公司药品阿奇霉素干混悬剂通过仿制药一致性评价","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203182149a2690ded&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241203182149a2690ded&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","00719","BK1191"],"gpt_icon":0},{"id":"2488998863","title":"山东新华制药股份(00719)：阿奇霉素干混悬剂通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2488998863","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488998863?lang=zh_cn&edition=full","pubTime":"2024-12-03 16:37","pubTimestamp":1733215046,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山东新华制药股份(00719)发布公告，近日，该公司全资子公司山东淄博新达制药有限公司(以下简称“新达制药”)收到国家药品监督管理局核准签发的阿奇霉素干混悬剂(以下简称“本品”)《药品补充申请批准通知书》，批准本品通过仿制药质量和疗效一致性评价。公告称，新达制药的阿奇霉素干混悬剂于2024年12月通过仿制药质量与疗效一致性评价，有利于丰富公司抗感染药物产品线，提升公司综合竞争优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1219638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00719","BK1515"],"gpt_icon":0},{"id":"2488624243","title":"新华制药获乳果糖口服溶液上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2488624243","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488624243?lang=zh_cn&edition=full","pubTime":"2024-12-02 17:32","pubTimestamp":1733131945,"startTime":"0","endTime":"0","summary":"近日，公司收到国家药品监督管理局核准签发的乳果糖口服溶液《药品补充申请批准通知书》，批准了该产品的上市许可持有人变更申请。乳果糖口服液主要用于慢性或习惯性便秘及肝性脑病的治疗。根据数据显示，2023年中国公立医疗机构乳果糖口服溶液的销售额约为17.69亿元。2024年前三季度，新华制药实现收入67.34亿元，归母净利润3.44亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202182526a2660b00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241202182526a2660b00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00719","BK1191","BK1515"],"gpt_icon":0},{"id":"2488705625","title":"山东新华制药股份(00719)收到国家药监局核准签发的乳果糖口服溶液(100ml:66.7g)《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2488705625","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488705625?lang=zh_cn&edition=full","pubTime":"2024-12-02 16:55","pubTimestamp":1733129722,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山东新华制药股份(00719)发布公告，近日，该公司收到国家药品监督管理局核准签发的乳果糖口服溶液(100ml:66.7g)(以下简称“本品”)《药品补充申请批准通知书》，该产品上市许可持有人转让申请获得批准。公告称，乳果糖口服溶液(100ml:66.7g)于2024年11月通过国家药品监督管理局审批，新华制药成为本品的上市许可持有人。该产品的上市，有利于丰富公司消化系统药物产品线，提升公司综合竞争优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1218981.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","00719","BK1191"],"gpt_icon":0},{"id":"2488562579","title":"山东新华制药股份(00719)盐酸艾司洛尔注射液(10ml：0.1g)获得《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2488562579","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488562579?lang=zh_cn&edition=full","pubTime":"2024-12-02 16:52","pubTimestamp":1733129576,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山东新华制药股份(00719)公布，近日，公司收到国家药品监督管理局核准签发的盐酸艾司洛尔注射液(10ml：0.1g)《药品补充申请批准通知书》，该产品上市许可持有人转让申请获得批准。根据《中华人民共和国药品管理法》及相关规定，经审查，本品此次申请事项符合药品注册的有关要求，同意按照《药品上市后变更管理办法(试行)》相关规定，批准本品上市许可持有人变更申请，发给《药品补充申请批准通知书》。新华制药盐酸艾司洛尔注射液(10ml：0.1g)的上市，有利于丰富公司心脑血管产品线，有助于提升公司产品的市场竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1218975.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","00719"],"gpt_icon":0},{"id":"2486390336","title":"南向资金11月27日净买入山东新华制药股份4.20万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2486390336","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486390336?lang=zh_cn&edition=full","pubTime":"2024-11-28 09:30","pubTimestamp":1732757409,"startTime":"0","endTime":"0","summary":"11月27日, 南向资金增持山东新华制药股份4.20万股，连续3日增持。截止当日收盘，港股通共持有山东新华制药股份9344.11万股，占流通股47.91%。山东新华制药股份近5个交易日下跌3.67%，港股通累计增持154.60万股；近20个交易日下跌2.20%，港股通累计增持219.70万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128093042abe485f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128093042abe485f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00719","BK1515"],"gpt_icon":0},{"id":"2486067498","title":"智通港股早知道 | 科技创新和技术改造贷款加速落地 华为将举办Mate品牌盛典","url":"https://stock-news.laohu8.com/highlight/detail?id=2486067498","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486067498?lang=zh_cn&edition=full","pubTime":"2024-11-26 07:38","pubTimestamp":1732577889,"startTime":"0","endTime":"0","summary":"华为将举办Mate品牌盛典11月26日下午，华为将举办Mate品牌盛典，新品包括华为Mate70系列、折叠屏手机Mate X6、MatePad Pro 13.2英寸、华为FreeBuds Pro 4、智界新S7、尊界S800等。I48为小分子一类新药，拟用于治疗精神分裂症。截至公告日，全球未有完全相同靶点和同适应症的药品上市。公司本次申报的I48临床申请获得受理，对公司近期经营业绩不会产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSTECH","07226","BK1179","02607","BK1144","BK1191","YANG","BK1197","BK1515","01478","HSCEI","00719","BK1096","01274","BK1504"],"gpt_icon":0},{"id":"2486703682","title":"山东新华制药股份(00719)：碳酸司维拉姆原料药取得FDA注册批准函","url":"https://stock-news.laohu8.com/highlight/detail?id=2486703682","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486703682?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:29","pubTimestamp":1732526990,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山东新华制药股份 发布公告，近日，该公司收到美国食品药品监督管理局核准签发的碳酸司维拉姆原料药FDA注册批准函。根据有关数据统计，截至2024年3月31日止的12个月内碳酸司维拉姆原料药全球消耗量600余吨。新华制药碳酸司维拉姆原料药于2024年11月顺利取得FDA药品注册批准函，有利于公司拓宽境外市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215416.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00719","BK1515","BK1191"],"gpt_icon":0},{"id":"2485010261","title":"南向资金11月20日净买入山东新华制药股份1.20万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2485010261","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485010261?lang=zh_cn&edition=full","pubTime":"2024-11-21 09:30","pubTimestamp":1732152607,"startTime":"0","endTime":"0","summary":"11月20日, 南向资金增持山东新华制药股份1.20万股，连续3日增持。截止当日收盘，港股通共持有山东新华制药股份9189.51万股，占流通股47.12%。山东新华制药股份近5个交易日下跌1.96%，港股通累计增持143.20万股；近20个交易日下跌2.28%，港股通累计减持65.10万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121093022a249ebc7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241121093022a249ebc7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","00719","BK1191"],"gpt_icon":0},{"id":"2483092485","title":"南向资金11月12日净卖出山东新华制药股份38.60万股 连续5日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2483092485","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483092485?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:30","pubTimestamp":1731461409,"startTime":"0","endTime":"0","summary":"11月12日，南向资金减持山东新华制药股份38.60万股连续5日减持。截止当日收盘，港股通共持有山东新华制药股份9046.31万股，占流通股46.38%。山东新华制药股份近5个交易日上涨1.14%，港股通累计减持162.26万股；近20个交易日上涨3.86%，港股通累计减持288.50万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093038abbb7e36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093038abbb7e36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00719","BK1515"],"gpt_icon":0},{"id":"2482718405","title":"港股异动 | 山东新华制药股份(00719)现涨近6% 全资子公司获批非布司他片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2482718405","media":"智通财经网","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482718405?lang=zh_cn&edition=full","pubTime":"2024-11-12 10:12","pubTimestamp":1731377561,"startTime":"0","endTime":"0","summary":"山东新华制药股份(00719)现涨近6%，截至发稿，涨6.25%，报6.46港元，成交额2302.17万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20241112/20241112101255_77072.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20241112/20241112101255_77072.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","BK1515","00719"],"gpt_icon":0},{"id":"2482718326","title":"山东新华制药股份盘中异动 股价大涨5.26%报6.400港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482718326","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482718326?lang=zh_cn&edition=full","pubTime":"2024-11-12 10:09","pubTimestamp":1731377394,"startTime":"0","endTime":"0","summary":"2024年11月12日早盘10时09分，山东新华制药股份股票出现波动，股价大幅上涨5.26%。截至发稿，该股报6.400港元/股，成交量269.54万股，换手率1.38%，振幅4.93%。资金方面，该股资金流入906.802万港元，流出497.174万港元。山东新华制药股份股票所在的药品行业中，整体涨幅为0.44%。其相关个股中，凯莱英、山东新华制药股份、康龙化成涨幅较大，振幅较大的相关个股有君圣泰医药-B、凯莱英、信达生物，振幅分别为11.30%、8.46%、7.37%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112100954abb7ab24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112100954abb7ab24&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00719","BK1191","BK1515"],"gpt_icon":0},{"id":"2482713506","title":"山东新华制药股份(00719)股价上升5.099%，现价港币$6.39","url":"https://stock-news.laohu8.com/highlight/detail?id=2482713506","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482713506?lang=zh_cn&edition=full","pubTime":"2024-11-12 10:09","pubTimestamp":1731377340,"startTime":"0","endTime":"0","summary":"[上升股]山东新华制药股份(00719) 股价在上午10:09比前收市价上升5.099%，现股价为港币$6.39。至目前为止，今日最高价为$6.39，而最低价为$6.1。总成交量为261.54万股，总成交金额为港币$1.647千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR241112804/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK1515","00719"],"gpt_icon":0},{"id":"2482799265","title":"【湾区早参】港交所发布《内地与香港资本市场互联互通十周年白皮书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2482799265","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482799265?lang=zh_cn&edition=full","pubTime":"2024-11-12 08:40","pubTimestamp":1731372027,"startTime":"0","endTime":"0","summary":"截至2024年9月底，沪深港通下合资格股票超过3,300只，已覆盖沪深港三地市场上市公司总市值的九成，成交规模的八成以上。此乃由于香港之消费市场疲弱所致。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OWRlOWUwM2UzYzc0YWVmOThhNzQ1ZDFlMmFkZGIzYjY4MTQyOTUwNzU2MTA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947505","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1504","BK1096","IE0032431581.USD","SG9999012736.USD","LU1046422090.SGD","09863","BK1161","CPI","LU0173614495.USD","BK1515","BK1119","BK1121","00551","LU0307460666.USD","SG9999012710.SGD","BK1549","SG9999012728.SGD","BK1603","09969","BK1550","BK1179","02628","01478","SG9999012744.USD","LU0588546209.SGD","BK1184","LU0287142896.SGD","BK1521","01610","BK1574","01705","BK1237","BK1168","BK1584","00719","BK1191"],"gpt_icon":0},{"id":"2482208324","title":"【港股通】山东新华制药股份(00719)非布司他片获药品注册证书 拟用于痛风症状的高尿酸血症","url":"https://stock-news.laohu8.com/highlight/detail?id=2482208324","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482208324?lang=zh_cn&edition=full","pubTime":"2024-11-11 17:29","pubTimestamp":1731317348,"startTime":"0","endTime":"0","summary":"据悉，非布司他为2-芳基噻唑衍生物，是一种黄嘌呤氧化酶抑制剂，通过抑制尿酸合成降低血清尿酸浓度，适用于具有痛风症状的高尿酸血症的长期治疗，使用方式为口服。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/ODZmNGUxMWEzNDY0MmFlZjFiZTZhNmUzMTczMTA1Mjk4MjYzMA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ODZmNGUxMWEzNDY0MmFlZjFiZTZhNmUzMTczMTA1Mjk4MjYzMA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947497","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719","YANG","BK1191","BK1515","HSCEI","HSTECH"],"gpt_icon":0},{"id":"2482120881","title":"新华制药：产品取得注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2482120881","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482120881?lang=zh_cn&edition=full","pubTime":"2024-11-11 17:17","pubTimestamp":1731316639,"startTime":"0","endTime":"0","summary":"每经AI快讯，新华制药11月11日晚间发布公告称，近日，山东新华制药股份有限公司之全资子公司山东淄博新达制药有限公司收到国家药品监督管理局核准签发的非布司他片《药品注册证书》，批准本品上市许可申请。产品名称为“非布司他片”。新华制药的董事长是贺同庆，男，学历背景为硕士；总经理是徐文辉，男，48岁，学历背景为大学学历。每经头条（nbdtoutiao）——“含胖量”大增，胖东来广东首家调改商超开业！不设利润目标，普通员工工资6000元起，日工作时长不超8小时(记者 陈鹏程)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111171807abb59bc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111171807abb59bc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00719","BK1515","BK1191"],"gpt_icon":0},{"id":"2482277451","title":"山东新华制药股份旗下非布司他片获药品注册证书  适用于具有痛风症状的高尿酸血症的长期治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2482277451","media":"格隆汇资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482277451?lang=zh_cn&edition=full","pubTime":"2024-11-11 16:55","pubTimestamp":1731315323,"startTime":"0","endTime":"0","summary":"格隆汇11月11日丨山东新华制药股份公布，近日，公司全资子公司山东淄博新达制药有限公司收到国家药品监督管理局核准签发的非布司他片《药品注册证书》，批准本品上市许可申请。非布司他为2-芳基噻唑衍生物，是一种黄嘌呤氧化酶抑制剂，通过抑制尿酸合成降低血清尿酸浓度，适用于具有痛风症状的高尿酸血症的长期治疗，使用方式为口服。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111165530abb58405&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111165530abb58405&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00719","BK1191","BK1515"],"gpt_icon":0},{"id":"2482277807","title":"山东新华制药股份(00719)：非布司他片获得《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2482277807","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482277807?lang=zh_cn&edition=full","pubTime":"2024-11-11 16:55","pubTimestamp":1731315306,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山东新华制药股份 发布公告，近日，公司全资子公司山东淄博新达制药有限公司收到国家药品监督管理局核准签发的非布司他片《药品注册证书》。根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求，批准注册，发给药品注册证书。新达制药申报的非布司他片于2024年11月通过国家药品监督管理局审批，有利于丰富公司产品系列，提升公司核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","00719"],"gpt_icon":0},{"id":"2482210138","title":"南向资金11月8日净卖出山东新华制药股份11.80万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2482210138","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482210138?lang=zh_cn&edition=full","pubTime":"2024-11-11 09:30","pubTimestamp":1731288610,"startTime":"0","endTime":"0","summary":"11月8日，南向资金减持山东新华制药股份11.80万股连续3日减持。截止当日收盘，港股通共持有山东新华制药股份9147.91万股，占流通股46.90%。山东新华制药股份近5个交易日上涨4.77%，港股通累计减持78.46万股；近20个交易日下跌2.23%，港股通累计减持249.16万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111093115a22abe68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111093115a22abe68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00719","BK1515","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xhzy.com","stockEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.1004},{"period":"6month","weight":0.1126},{"period":"1year","weight":0.041},{"period":"ytd","weight":0.0645}],"compareEarnings":[{"period":"1week","weight":0.0306},{"period":"1month","weight":-0.0371},{"period":"3month","weight":0.1311},{"period":"6month","weight":0.0687},{"period":"1year","weight":0.1862},{"period":"ytd","weight":0.1583}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"山东新华制药股份有限公司是一家主要从事化学原料药、制剂和医药中间体的开发、制造和销售的中国公司。该公司的产品主要包括安乃近、咖啡因、氨基比林、阿斯匹林、氢化可的松、吡哌酸、布洛芬、左旋多巴、吡哌酸片、复方甘草片和尼莫地平片等。该公司的产品销往中国国内与海外市场，包括美洲和欧洲等。","yearOnYearQuotes":[{"month":1,"riseRate":0.607143,"avgChangeRate":-0.014683},{"month":2,"riseRate":0.821429,"avgChangeRate":0.107857},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.005849},{"month":4,"riseRate":0.75,"avgChangeRate":0.110341},{"month":5,"riseRate":0.321429,"avgChangeRate":-0.003589},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.006604},{"month":7,"riseRate":0.571429,"avgChangeRate":0.006209},{"month":8,"riseRate":0.296296,"avgChangeRate":-0.041364},{"month":9,"riseRate":0.37037,"avgChangeRate":-0.017083},{"month":10,"riseRate":0.464286,"avgChangeRate":0.010896},{"month":11,"riseRate":0.535714,"avgChangeRate":0.01142},{"month":12,"riseRate":0.607143,"avgChangeRate":0.027551}],"exchange":"SEHK","name":"山东新华制药股份","nameEN":"SHANDONG XINHUA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供山东新华制药股份(00719)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"山东新华制药股份,00719,山东新华制药股份股票,山东新华制药股份股票老虎,山东新华制药股份股票老虎国际,山东新华制药股份行情,山东新华制药股份股票行情,山东新华制药股份股价,山东新华制药股份股市,山东新华制药股份股票价格,山东新华制药股份股票交易,山东新华制药股份股票购买,山东新华制药股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"山东新华制药股份(00719)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供山东新华制药股份(00719)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}